De Sousa SMC, et al. - This study was performed to evaluate the incidence of ipilimumab-induced hypophysitis (IH) at a quaternary melanoma referral centre. In addition, the authors determined whether cortisol or thyroid stimulating hormone (TSH) monitoring could predict IH onset. Findings revealed that TSH fall ≥ 80% could be an early marker of IH. During ipilimumab therapy, serial TSH measurement could be an inexpensive tool to expedite IH diagnosis.